prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
Company profile
Ticker
PRLD
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Prelude Therapeutics Inc.
SEC CIK
Corporate docs
IRS number
811384762
PRLD stock data
Latest filings (excl ownership)
S-3
Shelf registration
15 Feb 24
S-8
Registration of securities for employees
15 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
15 Feb 24
8-K
Prelude Therapeutics Announces $25 Million Private Placement
11 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
1 Nov 23
10-Q
2023 Q1
Quarterly report
3 Aug 23
8-K
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.94 mm | 19.94 mm | 19.94 mm | 19.94 mm | 19.94 mm | 19.94 mm |
Cash burn (monthly) | 3.52 mm | 3.01 mm | 11.13 mm | 10.69 mm | 8.56 mm | 8.87 mm |
Cash used (since last report) | 21.01 mm | 17.99 mm | 66.50 mm | 63.88 mm | 51.16 mm | 52.99 mm |
Cash remaining | -1.07 mm | 1.95 mm | -46.56 mm | -43.94 mm | -31.22 mm | -33.05 mm |
Runway (months of cash) | -0.3 | 0.6 | -4.2 | -4.1 | -3.6 | -3.7 |
Institutional ownership, Q3 2023
66.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 7 |
Closed positions | 2 |
Increased positions | 24 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 109.06 bn |
Total shares | 36.61 mm |
Total puts | 1.20 k |
Total calls | 200.00 |
Total put/call ratio | 6.0 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 10.91 mm | $33.71 bn |
Baker Bros. Advisors | 10.12 mm | $31.28 bn |
FMR | 5.13 mm | $15.86 bn |
Boxer Capital | 2.50 mm | $7.71 bn |
EcoR1 Capital | 1.16 mm | $3.58 bn |
BLK Blackrock | 1.07 mm | $3.30 bn |
T. Rowe Price | 1.07 mm | $3.30 mm |
Vanguard | 973.61 k | $3.01 bn |
Massachusetts Financial Services | 510.28 k | $1.58 bn |
Sio Capital Management | 350.00 k | $1.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Krishna Vaddi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.59 | 425,000 | 1.95 mm | 425,000 |
1 Mar 24 | Lim Bryant David | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.59 | 150,000 | 688.50 k | 150,000 |
1 Mar 24 | Peggy Scherle | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.59 | 150,000 | 688.50 k | 150,000 |
1 Mar 24 | Andrew Combs | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.59 | 150,000 | 688.50 k | 150,000 |
1 Mar 24 | Laurent Chardonnet | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.59 | 150,000 | 688.50 k | 150,000 |
News
JMP Securities Initiates Coverage On Prelude Therapeutics with Market Outperform Rating, Announces Price Target of $7
13 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
16 Feb 24
Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023
15 Feb 24